Genovis AB Share Price Nasdaq Stockholm
Equities
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
||
- SEK | - |
05-15 | Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Sales 2024 * | 137M 12.82M 1.01B | Sales 2025 * | 235M 21.96M 1.73B | Capitalization | 2.26B 211M 16.6B |
---|---|---|---|---|---|
Net income 2024 * | 31M 2.89M 228M | Net income 2025 * | 40M 3.73M 294M | EV / Sales 2024 * | 15.7 x |
Net cash position 2024 * | 109M 10.2M 803M | Net cash position 2025 * | 105M 9.82M 773M | EV / Sales 2025 * | 9.15 x |
P/E ratio 2024 * |
71.9
x | P/E ratio 2025 * |
25.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.42% |
Managers | Title | Age | Since |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 31/12/01 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 31/12/21 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 31/12/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 04/05/20 | |
Director/Board Member | 63 | 31/12/18 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 31/12/13 |
1st Jan change | Capi. | |
---|---|---|
-4.67% | 12.33B | |
-5.19% | 8.14B | |
+30.73% | 5.62B | |
-8.09% | 4.24B | |
-54.47% | 3.06B | |
+13.49% | 2.76B | |
-1.34% | 2.41B | |
+32.13% | 2.23B | |
-3.55% | 1.87B |